TrialClinical pharmacokinetics2016

Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study.

Laura Dickinson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.